Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
作者： Deborah A Nicoll-Griffith , James A Yergey , Laird A Trimble , José M Silva , Chun Li
DOI: 10.1016/S0960-894X(00)00538-2
关键词:
摘要: Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. include products oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none known human metabolites inhibits COX-1 nor contributes significantly to inhibition COX-2.
elsevier.com
sci-hub.se 参考文章(10)
James A. Yergey, Deborah A. Nicoll-Griffith, Denis Riendeau, Jean-Pierre Falgueyret, Laird Trimble, Pierre-Emmanuel Morin, Zhaoyin Wang, Serge Leger, Sophie Clas, Chi-C. Chan, José M. Silva, Oxidative Bioactivation of the Lactol Prodrug of A Lactone Cyclooxygenase-2 Inhibitor Drug Metabolism and Disposition. ,vol. 27, pp. 403- 409 ,(1999)
David L. DeWitt, Cox-2-selective inhibitors: the new super aspirins. Molecular Pharmacology. ,vol. 55, pp. 625- 631 ,(1999)
Chun. Li, Nathalie. Chauret, Yves. Ducharme, Laird A. Trimble, Deborah A. Nicoll-Griffith, James A. Yergey, Integrated application of capillary HPLC/continuous-flow liquid secondary ion mass spectrometry to discovery stage metabolism studies. Analytical Chemistry. ,vol. 67, pp. 2931- 2936 ,(1995) , 10.1021/AC00113A030
P Prasit, Z Wang, C Brideau, C.-C Chan, S Charleson, W Cromlish, D Ethier, J.F Evans, A.W Ford-Hutchinson, J.Y Gauthier, R Gordon, J Guay, M Gresser, S Kargman, B Kennedy, Y Leblanc, S Léger, J Mancini, G.P O'Neill, M Ouellet, M.D Percival, H Perrier, D Riendeau, I Rodger, P Tagari, M Thérien, P Vickers, E Wong, L.-J Xu, R.N Young, R Zamboni, S Boyce, N Rupniak, M Forrest, D Visco, D Patrick, The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Bioorganic & Medicinal Chemistry Letters. ,vol. 9, pp. 1773- 1778 ,(1999) , 10.1016/S0960-894X(99)00288-7
P. Brooks, P. Emery, J. F. Evans, H. Fenner, C. J. Hawkey, C. Patrono, J. Smolen, F. Breedveld, R. Day, M. Dougados, E. W. Ehrich, J. Gijon-Baños, T. K. Kvien, M. H. Van Rijswijk, T. Warner, H. Zeidler, Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 Rheumatology. ,vol. 38, pp. 779- 788 ,(1999) , 10.1093/RHEUMATOLOGY/38.8.779
C C Chan, I Rodger, C Brideau, D Ethier, M Gresser, S Kargman, G P O'Neill, S Boyce, M D Percival, S Leger, P Prasit, M J Forrest, A W Ford-Hutchinson, J Mancini, S Charleson, J Guay, J Y Gauthier, M Ouellet, W Cromlish, D Patrick, Y Leblanc, H Perrier, B Kennedy, J Evans, R Gordon, Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Journal of Pharmacology and Experimental Therapeutics. ,vol. 290, pp. 551- 560 ,(1999)
D Nicoll-Griffith, L Trimble, H Williams, R Rasori, J Yergey, R Zamboni, In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat. Drug Metabolism and Disposition. ,vol. 20, pp. 383- 389 ,(1992)
P. A. Leeson, L. A. Sorbera, J. Castaner, ROFECOXIB : PROP INN Drugs of The Future. ,vol. 23, pp. 1287- 1296 ,(1998)
T. D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, J. R. Vane, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 7563- 7568 ,(1999) , 10.1073/PNAS.96.13.7563
E EHRICH, A DALLOB, I DELEPELEIRE, A VANHECKEN, D RIENDEAU, W YUAN, A PORRAS, J WITTREICH, J SEIBOLD, P DESCHEPPER, Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clinical Pharmacology & Therapeutics. ,vol. 65, pp. 336- 347 ,(1999) , 10.1016/S0009-9236(99)70113-X